Drugs / 177Lu-LNC1003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06237491 | May → Nov 2025 | castration-resistant prostate carcinoma | Yantai LNC Biotechnology Singapore PTE. LTD. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-LNC1003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237491 ↗ |
| Modality | Other / unclassified | “radionuclide therapy” NCT06237491 ↗ |
| Route | Intravenous | “single-dose intravenous administration of 177Lu-LNC1003 Injection” NCT06237491 ↗ |